Comparative Pharmacology
Head-to-head clinical analysis: LEMTRADA versus LEQEMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEMTRADA versus LEQEMBI.
LEMTRADA vs LEQEMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.
None Documented
None Documented
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Terminal half-life approximately 7.6 days (range 5-12 days) after multiple doses; supports monthly dosing.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Primarily catabolized to amino acids; not excreted renally or hepatically in unchanged form.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody